The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

The FDA has approved clesrovimab -- sold as Enflonsia -- a new shot to prevent respiratory syncytial virus (RSV) infection in babies during their first RSV season, which typically lasts from fall ...

Clesrovimab is a monoclonal antibody (mAb) that protects against RSV subtypes A and B. Merck investigators presented the results of two phase 2b/3 trials at IDWeek in October.

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born ...

Clesrovimab joins nirsevimab, a long-acting monoclonal antibody approved in 2023, in the arsenal to help protect infants and children against RSV. All seven voted yes to include clesrovimab in the ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...